Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
becotatug vedotin + sacituzumab tirumotecan
- Development stage
- Unknown
- Lead developer
- Lepu Biopharma
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This combination therapy involves the co-administration or comparative use of two antibody-drug conjugates (ADCs): becotatug vedotin (MRG003) and sacituzumab tirumotecan (SKB264/MK-2870). Becotatug vedotin is an EGFR-targeted ADC that delivers the microtubule-disrupting agent monomethyl auristatin E (MMAE) via a cleavable valine-citrulline linker. Sacituzumab tirumotecan is a TROP2-targeted ADC that utilizes a humanized monoclonal antibody (sacituzumab) conjugated to a novel topoisomerase I inhibitor payload (tirumotecan) through a carbonate-based linker. These agents are being evaluated in clinical trials, such as a Phase II study for recurrent or metastatic salivary gland carcinoma (NCT06414330), where they are assigned based on the expression of EGFR and TROP2 on tumor cells. The strategy aims to provide targeted cytotoxic delivery to tumors that overexpress these common epithelial markers, potentially overcoming resistance to standard therapies in head and neck cancers.
- Other names
- MRG003 + SKB264
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)TUBB (Tubulin (alpha and beta subunits))TOP1 (DNA Topoisomerase I)TACSTD2 (Tumor-associated calcium signal transducer 2)
Beyond the preview
Go deeper on becotatug vedotin + sacituzumab tirumotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on becotatug vedotin + sacituzumab tirumotecan.